~~<i id='B2D0F6D9FB'><strike id='B2D0F6D9FB'><tt id='B2D0F6D9FB'><pre id='B2D0F6D9FB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

Wikipedia

author：knowledge 2025-09-06 08:39:31 - browse：915

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Use doctors trained outside the U.S. to ease the physician shortage

hotspot

focus

hotspot

AdobeUsingonlineplatformssuchasGoFundMetosolicitdonationsforhealth-relatedneedscanhelppeopleaccessle

WSS

Security flaws in third

FDA weighs limits of animal data in assessing artificial wombs

Hubble vs. James Webb telescope images: See the difference

How Robert F. Kennedy Jr. distorted vaccine science

Neurocrine congenital adrenal hyperplasia trial succeeds

The unintended consequences of overturning Roe v. Wade

entertainment

Wikipedia

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Prescription digital therapeutics are key to pharma’s future

At least 13 dead in Texas as scorching temps continue

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Hollywood unions extend contract negotiations for actors

FDA panel to weigh safety of artificial wombs for preterm births

The high cost of giving birth even with insurance

House panel takes first step toward fixing drug shortages

Cancer drug shortages should be causing more outrage

The wait for US passports is creating travel purgatory and snarling summer plans

focus

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

How the messy conversation about Dolly changed bioethics

AstraZeneca lung cancer study comes in below expectations

Crowdfunding for unproven stem cell procedures spreads misinformation

Neurocrine congenital adrenal hyperplasia trial succeeds

Information blocking fines are now fair game in health care

focus

hotspot

hotspot

hotspot